UOBAM FTSE China A50 Index ETF

Fund Description

Key Features

• 1

  Broader and more representative exposure

  The ETF transitioned on 25 March 2025 from tracking only Shanghai SSE‑listed stocks to the more comprehensive FTSE China A50 Index, now including both Shanghai (39 stocks) and Shenzhen (11 stocks), enriching sector diversity. 

  By extending into Shenzhen listings, the fund captures more innovation‑driven firms in green energy, EVs, and tech—areas underrepresented in the former SSE‑only basket.

  
  This broader coverage provides a more balanced reflection of China’s capital markets during its tech‑led transformation.

  
  As of March 2025, the allocation stands at 39 stocks from Shanghai and 11 from Shenzhen, underscoring its expanded breadth

• 2

  Focus on high‑growth sectors

  The ETF emphasizes exposure to sectors benefiting from China’s macroeconomic priorities, such as consumer staples, healthcare, green energy, and financials.
   

  Top index holdings include Kweichow Moutai (11.8%), CATL (6.8%), China Merchants Bank (5.5%), China Yangtze Power (4.1%), BYD (4%), and Ping An Insurance (3.3%)—all positioned to capitalize on domestic growth and innovation.
   

  BYD’s 34% year‑on‑year net profit growth in 2024 and its 45.1% five‑year annualized return highlight the performance potential of these growth‑oriented companies.

  
  Sector breakdown (as of Jan 2025): Financials 33.9%, Consumer Staples 20.5%, Industrials 14.3%, showing a tilt toward stable yet growth-enabling industries 

• 3

  Accessibility and simplicity

  Listed in SGD (ticker JK8) and USD (VK8) on SGX, the ETF is easy to trade via standard Singapore brokerage accounts.

  
  It enables investors to access China A‑share exposure without navigating foreign platforms or directly handling RMB, simplifying the investment process .

  
  Eligibility under the Supplementary Retirement Scheme (SRS) enhances its appeal for retirement-saving investors seeking diversification.

  
  The management fee of 0.45% per annum (as of 26 March 2025) keeps it cost‑efficient compared to actively managed alternatives